0001209191-24-005081.txt : 20240326
0001209191-24-005081.hdr.sgml : 20240326
20240326163042
ACCESSION NUMBER: 0001209191-24-005081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240322
FILED AS OF DATE: 20240326
DATE AS OF CHANGE: 20240326
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knight Jeff E.
CENTRAL INDEX KEY: 0001881007
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 24784055
MAIL ADDRESS:
STREET 1: CRINETICS PHARMACEUTICALS, INC.
STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-03-22
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001881007
Knight Jeff E.
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
0
1
0
0
Chief Operating Officer
0
Common Stock
2024-03-22
4
M
0
30000
23.98
A
84939
D
Common Stock
2024-03-22
4
S
0
30000
44.22
D
54939
D
Common Stock
2024-03-22
4
S
0
2359
45.39
D
52580
D
Stock Option (right to buy)
23.98
2024-03-22
4
M
0
30000
0.00
D
2031-09-01
Common Stock
30000
130000
D
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.22 per share. The range of sales prices on the transaction date was $44.00 to $44.52 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Marc Wilson, as attorney-in-fact
2024-03-26